CAR-T therapy in Turkey: Safe and advanced treatment for blood cancers

What is CAR-T Therapy?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a breakthrough cellular immunotherapy designed to treat certain blood cancers, including lymphomas, leukemias, and multiple myeloma. Its revolutionary principle is simple yet powerful: reprogram the patient's own immune cells to become targeted weapons against cancer.

How CAR-T works?

The effectiveness of CAR-T therapy relies on a seamless chain of steps, where any disruption can compromise safety or results. This is why treatment in a certified, integrated center is essential.

1. Collection (Apheresis): T-cells are carefully collected from the patient in a specialized unit under expert supervision.
2. Genetic engineering: In the laboratory, these cells are reprogrammed to express the CAR receptor, transforming them into precision “hunters” of cancer cells.
3. Expansion: CAR-T cells are multiplied under strict sterile conditions to reach a therapeutic dose.
4. Infusion: The engineered cells are reinfused into the patient in a fully monitored hospital environment.
5. Monitoring: After infusion, patients are closely observed for immune reactions, including cytokine release syndrome (CRS) or neurological effects, while treatment effectiveness is evaluated.

Seamless medical coordination

Every step demands advanced infrastructure and rigorous coordination between clinical teams, cell therapy laboratories, and hospital pharmacies. Turquie Santé's partner centers, all FACT/JACIE-certified, are specifically structured to ensure this technical, scientific, and safety continuity.

With Turquie Santé, we don't just explain the process; we manage it from start to finish. We coordinate all teams, ensure critical deadlines are met, and guarantee full traceability of your cells. This approach transforms a complex scientific procedure into a safe, controlled, and accessible treatment pathway.

Which blood cancers can be treated with CAR-T therapy?

CAR-T therapy is not a first-line treatment. It is a targeted rescue option for specific blood cancers when standard therapies, including chemotherapy, immunotherapy, or stem cell transplantation, have failed.

Its effectiveness relies on precise indications and careful patient selection, which is why an individualized medical assessment is essential.

Validated indications (per international guidelines)

Currently, CAR-T therapy is primarily indicated for patients with:

• Aggressive B-cell lymphomas: Diffuse large B-cell lymphoma (DLBCL),follicular lymphoma, or mantle cell lymphoma, typically after at least two prior treatment lines.
• B-cell acute lymphoblastic leukemia (ALL): In children and adults with relapsed or refractory disease.
• Multiple myeloma: For patients with disease resistant to multiple prior therapies, including proteasome inhibitors and immunomodulatory drugs.

These indications follow strict international protocols and require individualized medical validation before proceeding.

Eligibility criteria

A diagnosis alone is not sufficient for CAR-T therapy. Final eligibility depends on a multidisciplinary assessment that considers:

• Disease status: Tumor biology, disease burden, and prior treatments.
• Patient's overall condition: Heart, lung, kidney, and neurological function.
• Contraindications: Active uncontrolled infections or certain autoimmune conditions.
• Ability to tolerate side effects: Including cytokine release syndrome (CRS) or neurological toxicities.

Our rigorous evaluation at Turquie Santé

At Turquie Santé, we ensure that CAR-T therapy is truly a viable and safe option for you before any commitment. Our structured evaluation process is designed to provide clarity, safety, and peace of mind.

Step 1: Comprehensive medical review

Our dedicated medical board conducts a full analysis of your complete medical history, including biopsies, imaging scans, lab results, and previous treatment reports. This ensures that every clinical factor is considered before moving forward.

Step 2: Preliminary center assessment

Your case is fully anonymized and submitted confidentially to our FACT/JACIE-certified partner center in Turkey. Their expert team performs an initial feasibility review, evaluating whether CAR-T therapy is medically appropriate for your condition.

Step 3: Clear, honest reporting & treatment pathway

You receive a transparent assessment based on medical facts:

• If CAR-T therapy is suitable, we provide a detailed treatment plan and timeline.
• If it is not suitable, we explain the medical reasoning clearly and, with your consent, explore other advanced therapy options available in Turkey.

This thorough evaluation is typically completed within 7 business days, allowing you to make informed decisions quickly and confidently.

The transformative potential of CAR-T cell therapy

CAR-T therapy is a groundbreaking advancement in the treatment of certain blood cancers, offering hope and potential remission for patients who have not responded to standard treatments.

Key benefits include:

• Potential for long-term remission: Some patients achieve deep and durable remission, even after multiple prior therapies have failed.
• Personalized treatment: CAR-T uses the patient's own immune cells, reducing risks such as immune rejection or graft-versus-host disease (GvHD).
• Precise cancer targeting: Engineered CAR-T cells specifically recognize and attack cancer cells, while minimizing harm to healthy tissue.
• Alternative to stem cell transplant: In eligible patients, CAR-T may delay or replace the need for a traditional stem cell transplant, offering more flexibility in treatment planning.
• World-class safety and expertise: Administered in FACT/JACIE-certified centers, patients benefit from cutting-edge care, advanced monitoring, and strict international safety standards.

Limitations and side effects

Open discussion about the challenges of CAR-T therapy is essential for informed consent, realistic expectations, and most importantly, for ensuring your safe medical management. The information below is not meant to discourage, but to demonstrate our thorough and proactive approach to your care.

Key limitations to consider

Important considerations for CAR-T therapy include :

• Strict medical indications: CAR-T therapy is approved only for specific blood cancers and clinical situations. It is not a universal cancer treatment, which makes precise patient selection critical.
• High treatment complexity: The process involves cell collection, genetic engineering, controlled manufacturing, and reinfusion. This complexity is why CAR-T can only be safely delivered in highly specialized, integrated centers.
• Evolving long-term evidence: While results are highly promising, long-term outcome data continue to evolve. Our partner centers actively contribute to international registries and follow the latest global recommendations to ensure evidence-based care.

Proactive management of potential side effects

Our FACT/JACIE-certified partner centers are equipped with standardized protocols, specialist teams, and advanced technology to promptly identify and manage side effects.

Our commitment to safety

Turquie Santé ensures the strict application of internationally validated side-effect management protocols. A dedicated medical coordinator maintains continuous communication between you, your family, and the treating medical team, particularly during the critical post-infusion phase, when close monitoring is essential.

In CAR-T therapy, the quality of monitoring and follow-up is part of the treatment itself. Choosing the right environment makes all the difference.